tiprankstipranks
Advertisement
Advertisement
Revolution Medicines price target raised to $201 from $192.10 at Wedbush
PremiumThe FlyRevolution Medicines price target raised to $201 from $192.10 at Wedbush
9d ago
Revolution Medicines price target raised to $230 from $195 at Oppenheimer
Premium
The Fly
Revolution Medicines price target raised to $230 from $195 at Oppenheimer
9d ago
Revolution Medicines price target raised to $203 from $182 at RBC Capital
Premium
The Fly
Revolution Medicines price target raised to $203 from $182 at RBC Capital
9d ago
Revolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)
PremiumThe FlyRevolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)
9d ago
Revolution Medicines price target raised to $192.10 from $181 at Wedbush
Premium
The Fly
Revolution Medicines price target raised to $192.10 from $181 at Wedbush
23d ago
Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target
Premium
Ratings
Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target
23d ago
EMA accelerates assessment of Revolution Medicines daraxonrasib
PremiumThe FlyEMA accelerates assessment of Revolution Medicines daraxonrasib
1M ago
Revolution Medicines price target raised to $215 from $185 at Mizuho
Premium
The Fly
Revolution Medicines price target raised to $215 from $185 at Mizuho
1M ago
Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target
Premium
Ratings
Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100